Medicenna Therapeutics (TSE:MDNA) Announces Earnings Results

Medicenna Therapeutics (TSE:MDNA) announced its quarterly earnings data on Thursday. The company reported C($0.05) earnings per share (EPS) for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%.

Medicenna Therapeutics Stock Performance

Shares of Medicenna Therapeutics stock opened at C$0.76 on Friday. Medicenna Therapeutics has a 52-week low of C$0.74 and a 52-week high of C$1.97. The company has a quick ratio of 4.65, a current ratio of 11.40 and a debt-to-equity ratio of 0.88. The company’s 50-day simple moving average is C$0.98 and its 200-day simple moving average is C$1.10. The firm has a market cap of C$63.39 million, a price-to-earnings ratio of -4.47 and a beta of 2.87.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.